KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Change in Inventory: 2009-2024

Historic Change in Inventory for Biomarin Pharmaceutical (BMRN) over the last 16 years, with Dec 2024 value amounting to $63.5 million.

  • Biomarin Pharmaceutical's Change in Inventory rose 245.09% to $26.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $133.1 million, marking a year-over-year increase of 50.58%. This contributed to the annual value of $63.5 million for FY2024, which is 59.55% down from last year.
  • According to the latest figures from FY2024, Biomarin Pharmaceutical's Change in Inventory is $63.5 million, which was down 59.55% from $157.1 million recorded in FY2023.
  • In the past 5 years, Biomarin Pharmaceutical's Change in Inventory registered a high of $157.1 million during FY2023, and its lowest value of $35.1 million during FY2021.
  • Over the past 3 years, Biomarin Pharmaceutical's median Change in Inventory value was $68.3 million (recorded in 2022), while the average stood at $96.3 million.
  • As far as peak fluctuations go, Biomarin Pharmaceutical's Change in Inventory skyrocketed by 130.07% in 2023, and later slumped by 59.55% in 2024.
  • Over the past 5 years, Biomarin Pharmaceutical's Change in Inventory (Yearly) stood at $61.2 million in 2020, then slumped by 42.67% to $35.1 million in 2021, then spiked by 94.71% to $68.3 million in 2022, then surged by 130.07% to $157.1 million in 2023, then crashed by 59.55% to $63.5 million in 2024.